Compare KRRO & AXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRRO | AXR |
|---|---|---|
| Founded | 2014 | 1961 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 150.0M | 144.1M |
| IPO Year | 2019 | 2010 |
| Metric | KRRO | AXR |
|---|---|---|
| Price | $13.68 | $27.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 1 |
| Target Price | ★ $34.80 | $30.00 |
| AVG Volume (30 Days) | ★ 197.4K | 10.9K |
| Earning Date | 05-06-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.60 |
| EPS | N/A | ★ 1.68 |
| Revenue | $6,392,000.00 | ★ $12,831,000.00 |
| Revenue This Year | N/A | $12.43 |
| Revenue Next Year | N/A | $4.48 |
| P/E Ratio | ★ N/A | $16.79 |
| Revenue Growth | ★ 181.46 | N/A |
| 52 Week Low | $5.20 | $17.61 |
| 52 Week High | $55.89 | $29.00 |
| Indicator | KRRO | AXR |
|---|---|---|
| Relative Strength Index (RSI) | 59.66 | 53.34 |
| Support Level | $12.17 | $19.45 |
| Resistance Level | $15.11 | $28.52 |
| Average True Range (ATR) | 1.07 | 1.62 |
| MACD | 0.17 | -0.11 |
| Stochastic Oscillator | 67.20 | 70.91 |
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.